Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prevalence of Fibromyalgia in Israel

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2011 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01203865
First received: September 15, 2010
Last updated: October 10, 2011
Last verified: October 2011

September 15, 2010
October 10, 2011
October 2010
November 2011   (final data collection date for primary outcome measure)
Prevalence of fibromyalgia in the Israeli population [ Time Frame: 9 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01203865 on ClinicalTrials.gov Archive Site
Demographic data on fibromyalgia patients [ Time Frame: 9 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Prevalence of Fibromyalgia in Israel
Prevalence of Fibromyalgia in Israel
The prevalence of fibromyalgia syndrome in the Israeli population is of importance fro planning resource allocation of medical expenditure as well as for identifying demographic and ethnic differences of this unique population compared with other western samples. In the current study the investigators aim at estimating the prevalence of fibromyalgia in this population. For this purpose a two - stage process will be used. First, a population survey will be conducted by telephone, screening for widespread pain and fatigue in the general population. This survey will use the London Fibromyalgia Epidemiology Study Screening Questionnaire. Second, a sample of patients attending the rheumatology clinic will be surveyed with this tool and will be examined in order to determine the actual proportion of patients fulfilling ACR criteria for fibromyalgia. This will enable us to calculate the positive predictive value of the London Fibromyalgia Epidemiology Study Screening Questionnaire in our population and hence to calculate the prevalence of fibromyalgia in the population.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Probability Sample
Telephone survey - general population over age 18 Rheumatology patients - patients attending the rheumatology clinic for any reason
Fibromyalgia
Not Provided
Not Provided
Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010 Jun;39(6):448-53. doi: 10.1016/j.semarthrit.2008.12.003.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
1200
March 2012
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Individuals over 18 who consent to answer the survey questions
Both
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT01203865
0303-10-TLV, WS573984
No
Not Provided
Not Provided
Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
Pfizer
Principal Investigator: Jacob N Ablin, MD Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP